KAM
NERV icon

Kazazian Asset Management’s Minerva Neurosciences NERV Stock Holding History

Kazazian Asset Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,253
Closed -$126K – 74
2018
Q3 		$126K Hold
1,253
– – 0.12% 86
2018
Q2 		$83K Sell
1,253
-48
-4% -$2.92K 0.08% 81
2018
Q1 		$65K Hold
1,301
– – 0.07% 82
2017
Q4 		$63K Buy
+1,301
New +$64.5K 0.06% 79

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
IVAV
Index Venture Associates V St. Helier, Channel Islands, Jersey $1.46M AUM 88.05% 1-Year Est. Return

Kazazian Asset Management's NERV Position: Q4 2018 in Review

Kazazian Asset Management sold out of Minerva Neurosciences (NERV) in Q4 2018, closing a stake of 1,253 shares — an estimated $126K sold.

Kazazian Asset Management first reported a position in NERV in Q4 2017 and held it in 4 quarters. The position peaked at $126K in Q3 2018. 84 funds tracked by Wall St. Rank hold NERV as of Q4 2018.

  • Kazazian Asset Management reported no remaining Minerva Neurosciences position as of Q4 2018 after selling out during the quarter.
  • Kazazian Asset Management sold 1,253 Minerva Neurosciences shares in Q4 2018, an estimated $126K.
  • Kazazian Asset Management first reported a position in Minerva Neurosciences in Q4 2017 and held it in 4 quarters.
  • Kazazian Asset Management's Minerva Neurosciences position peaked at $126K in Q3 2018.
  • 84 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2018.

Based on Kazazian Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.